This study is in progress, not accepting new patients

Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery

a study on Breast Cancer

Eligibility: for females ages 45 years and up (full criteria)
Location: at UC Irvine UCSF
Dates: study started May 2012
completion around December 2028
Principal Investigator: by Michael Alvarado (ucsf)

Michael Alvarado

Description

Summary

This phase IV trial studies the side effects of intraoperative radiation therapy and how well it works in treating patients with breast cancer undergoing breast-conserving surgery. Delivering radiation one time to the area where the tumor was removed while the patient is still in the operating room may kill any residual tumor cells and may be as effective as standard radiation therapy in patients with early stage breast cancer.

Official Title

Targeted Intraoperative Radiotherapy United States (TARGIT-US) Phase IV Registry Trial: A Registry Trial of Targeted Intraoperative Radiation Therapy Following Breast-conserving Surgery

Details

PRIMARY OBJECTIVES:

To establish eligibility criteria based on previously published trials and studies in order to allow women who meet these criteria to receive intraoperative radiation therapy (IORT) on an Institutional Review Board (IRB)-approved protocol.

II. To systematically collect and assess acute and long-term toxicity and outcomes in larger cohort of patients.

III. To study the efficacy and toxicity of breast radiotherapy given intra-operatively as a single fraction after breast conserving surgery, with or without whole breast radiation, as indicated by pathologic risk factors, in women with early stage breast cancer.

IV. In-breast local failure and patterns of in-breast failure. V. Ipsilateral regional nodal failure. VI. Toxicity and morbidity. VII. Relapse-free survival. VIII. Overall survival.

OUTLINE:

Patients undergo IORT in a single fraction over 15-40 minutes at the time of standard of care lumpectomy.

After completion of study treatment, patients are followed up within 6 weeks and then every 6 months for 3 years and yearly for 2 years.

Keywords

Stage IA Breast Cancer, Stage IIA Breast Cancer, Breast Neoplasms, Intraoperative Radiation Therapy, Laboratory Biomarker Analysis

Eligibility

You can join if…

Open to females ages 45 years and up

Suitable for breast conserving surgery
T1 and T2 (< 3.5 cm), N0, M0

You CAN'T join if...

Axillary lymph node positive breast cancer
Tumor size > 3.5 cm
Extensive intraductal component (EIC >= 25% of the lumpectomy specimen involved with ductal carcinoma in situ), as assessed on surgical pathologic lumpectomy specimen
Multicentric cancer in the same breast as diagnosed by clinical examination, mammography, ultrasound; magnetic resonance imaging (MRI) or pathologic assessment, not amenable to excision with negative margins with a single lumpectomy
Inability to assess pathologic margin status
Synchronous bilateral breast cancer at the time of diagnosis
Ipsilateral breast had a previous cancer and/or prior in-field radiation
Patients known to have BRCA1/2 gene mutations (testing for gene mutations is not required)
Patients undergoing primary systemic treatment (hormones or chemotherapy) as initial treatment with neoadjuvant reducing tumor size
Previous history of malignant disease does not preclude entry if the expectation of relapse-free survival at 10 years or greater
Any factor included as exclusion criteria in the participating center's treatment policy statement
Additional exclusion criteria for University of California San Francisco (UCSF) (as laid out in the Treatment Policy):
- Patients under the age of 50
- Estrogen receptor negative (as defined in Treatment Policy under "Pathology")
- Human epidermal growth factor receptor 2 (HER2) positive (as defined in Treatment Policy under "HER2")
- Lymphovascular invasion
- High grade
- Tumors > 3 cm
- Node positive patients
- Prior chemotherapy or hormone therapy

Locations

University of California, Irvine
Irvine California 92617 United States
University of California, San Francisco
San Francisco California 94143 United States
Dignity Health - California Hospital Medical Center
Los Angeles California 90015 United States
Alta Bates Summit Medical Center-Herrick Campus
Berkeley California 94704 United States
John Muir Medical Center-Walnut Creek
Walnut Creek California 94598 United States

Lead Scientist at University of California Health

Michael Alvarado (ucsf)
Dr. Michael Alvarado is a cancer surgeon who cares for patients with breast cancer and melanoma at the UCSF Helen Diller Family Comprehensive Cancer Center at Mount Zion. In his research, Alvarado conducts trials of radiation therapy for breast cancer. He also studies blood-based and molecular markers with the goal of improving breast cancer screening.

Details

Status: in progress, not accepting new patients
Start Date: May 2012
Completion Date: December 2028 (estimated)
Sponsor: University of California, San Francisco
ID: NCT01570998
Study Type: Interventional
Participants: About 1259 people participating
Last Updated: February 4, 2025